Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

BACKGROUND/PURPOSE: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. METHODS: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca) and/or mRNA (mRNA-1273, Moderna) vaccines. Fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sheng, Wang-Huei, Chang, Sui-Yuan, Lin, Pin-Hung, Hsieh, Ming-Ju, Chang, Hao-Hsiang, Cheng, Chien-Yu, Yang, Hung-Chih, Pan, Ching-Fu, Ieong, Si-Man, Chao, Tai-Ling, Chen, Jang-Pin, Cheng, Shu-Hsing, Chang, Shan-Chwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Formosan Medical Association. Published by Elsevier Taiwan LLC. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926322/
https://www.ncbi.nlm.nih.gov/pubmed/35305895
http://dx.doi.org/10.1016/j.jfma.2022.02.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926322/
https://www.ncbi.nlm.nih.gov/pubmed/35305895
http://dx.doi.org/10.1016/j.jfma.2022.02.020

Ejemplares similares